ARTICLE SYNOPSIS...After reaching a multiyear high above $49 in December 2005, Citigroup corrected to $45 and now is on an upleg again, nearing a target.
ARTICLE SYNOPSIS...DISH Network Corp has recovered from all its previous losses. The price action near this resistance has to be observed carefully.
ARTICLE SYNOPSIS...The Dow Jones Industrial Average has entered a support zone that marks the make-or-break level for the medium-term uptrend.
ARTICLE SYNOPSIS...FTSE 100 works its way high towards key retracements and remains in uptrend.
ARTICLE SYNOPSIS...Gold bugs are getting excited about buying gold once again since the precious metal is so close to making a new high, but caution is the order of the day. According to the Elliott wave theory, gold is about to go down and not up.
ARTICLE SYNOPSIS...Statistical analysis shows the Dow Jones Industrial Average is nearing the end of its long-term upward trend.
ARTICLE SYNOPSIS...Up by more than 36% in the past 14 weeks, shares of Macerich Co. are near an important cycle high.
ARTICLE SYNOPSIS...Divergence + Confirmation = Reversal. Is the Nasdaq ready to roll?
ARTICLE SYNOPSIS...The Singapore Straits Times fell off a cliff in May but has yet to become oversold as it nears support.
ARTICLE SYNOPSIS...Statistical analysis is used here to show that the uptrend of the Dow Jones Industrial Average is in its final stage.
ARTICLE SYNOPSIS...Always anticipate the election cycle.
ARTICLE SYNOPSIS...As of late, discussion about the Standard & Poor's 500 index has been rife with citations from THE STOCK TRADER'S ALMANAC that cede 2005 to the bears based on its poor January performance. Unfortunately, articles also tell of the great retu
ARTICLE SYNOPSIS...The US Dollar Index has firmed over the last few months, but has yet to provide the spark needed to change the long-term downtrend.
ARTICLE SYNOPSIS...This pharmaceutical stock trades in both side of the border and is focused on the research, development, and commercialization of immune modulation therapy for the treatment of cardiovascular and other inflammatory diseases.
ARTICLE SYNOPSIS...After hitting a two-year high in the mid-$30 range and a low of $16, where is this stock headed?